A Phase I, Pharmacokinetic, and Treatment Duration and Escalation Study of Intravenous Intoplicine Administered as a 5 to 21-Day Continuous Infusion Every 4 Weeks
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Intoplicine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Sanofi Genzyme
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2005 New trial record.